Supplement evidence

033 / 575Joint/skin

Collagen peptides

View my plan →

The short answer

Some trials report modest improvements in joint symptoms or skin hydration and elasticity.

Evidence and scope: Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Product-specific studies and bias limit certainty; collagen is not superior complete protein for muscle.
Before deciding: Check allergens, product testing, and total protein needs.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Joint symptoms10–15 g/day hydrolyzed collagen or gelatin is commonly studied

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

Skin outcomes2.5–10 g/day collagen peptides in short trials

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityWater-soluble

Water-soluble or readily water-dispersible. This does not mean excess is always harmless.

How it is commonly taken

Vitamin C-containing food supports collagen synthesis; product form matters.

Do not combine casually

Check fish, bovine, porcine, or chicken allergens and product testing; evidence is outcome-specific.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger

27unique primary studies represented

1,996unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2025

Does not support the tested claimPMID 40324552

Effects of collagen supplements on skin aging: a systematic review and meta-analysis of randomized controlled trials

All trials pooled favored collagen, but non-pharmaceutical-funded and high-quality subgroups found no benefit. The authors concluded that current clinical evidence does not support collagen for preventing or treating skin aging.

Published: 2025n=1,474 participants23 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 23 randomized trials with funding and quality subgroup analyses
Population: 1,474 mostly adult participants in oral collagen skin trials
Intervention: Oral collagen supplements versus control
Outcome: Skin hydration, elasticity, and wrinkles

Open research record ↗

2018

Mixed or qualifiedPMID 29337906

Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women

Bone density and formation-marker changes favored the collagen product, but absolute changes were small, 29 participants did not complete, and this single product-specific trial does not establish fracture prevention.

Published: 2018Duration: 12 monthsn=131 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: 131 postmenopausal women with age-related low bone mineral density; 102 completed
Intervention: Specific collagen peptides 5 g/day or placebo
Outcome: Lumbar-spine and femoral-neck bone mineral density and bone-turnover markers

Funding or conflict note: One author was affiliated with the Collagen Research Institute; the trial tested a specific branded peptide formulation.

Open research record ↗

2016

Supports a specific usePMID 26822714 · NCT02237989

Efficacy and tolerability of undenatured type II collagen supplementation in knee osteoarthritis

The proprietary undenatured type II collagen product improved WOMAC scores versus placebo and glucosamine–chondroitin. This does not establish equivalent benefit for ordinary hydrolyzed collagen powders.

Published: 2016Duration: 180 daysn=191 participants

Study design and methods

Design: Multicenter randomized, double-blind, placebo-controlled trial
Population: 191 adults with knee osteoarthritis
Intervention: UC-II 40 mg/day, glucosamine hydrochloride plus chondroitin, or placebo
Outcome: WOMAC pain, stiffness, function, and safety

Funding or conflict note: The trial evaluated InterHealth's proprietary UC-II ingredient and included company-affiliated authors; this is formulation-specific evidence.

Open research record ↗

2015

Mixed or qualifiedPMID 26353786

Collagen peptide supplementation with resistance training in elderly sarcopenic men

Both groups improved with training; collagen produced larger changes in fat-free mass and strength. The small all-male trial compared collagen with a non-protein placebo, not with an adequate high-quality protein supplement.

Published: 2015Duration: 12 weeksn=53 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled training trial
Population: 53 men over 65 with class I or II sarcopenia
Intervention: Collagen peptides 15 g/day or silica placebo after supervised resistance training
Outcome: Fat-free mass, fat mass, and quadriceps strength

Funding or conflict note: One author was affiliated with the Collagen Research Institute, and the tested product was a specific commercial collagen peptide preparation.

Open research record ↗

2008

Mixed or qualifiedPMID 18416885

24-week study on the use of collagen hydrolysate in athletes with activity-related joint pain

Several pain ratings improved, but one third of randomized participants were not evaluable and the population had no diagnosed joint disease. The result supports only a cautious, product-specific possibility of symptom relief.

Published: 2008Duration: 24 weeksn=147 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: 147 athletes without diagnosed joint disease; only 97 were evaluable
Intervention: CH-Alpha collagen hydrolysate 10 g/day or placebo
Outcome: Activity-related joint pain, mobility, and inflammation ratings

Funding or conflict note: GELITA Health sponsored the research and supplied the tested collagen product.

Open research record ↗

Unscreened discovery appendix—not evidence115 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed systematic-review index Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.